Answer
It targets abnormal FLT3 signalling, so the AML must have a confirmed FLT3 mutation before treatment is started.
Sources for this answer
- Gilteritinib Astellas 40 mg film-coated tablets — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.